The Pharmaceutical Benefits Scheme (Australia) has added a low oestrogen dose combined oral contraceptive (COC) pill for the first time to its schedule of subsidised medicines from 1 July 2013.
This product is Femme-Tab ED 20/100, which AFT Pharmaceuticals has introduced to the Australian market, complete with PBS subsidisation.
Femme-Tab ED 20/100 tablets contain levonorgestrel 100 micrograms and ethinyloestradiol 20 micrograms.
Full details of Femme-Tab ED 20/100, including indications and usage, contraindications, adverse reactions and interactions with other medications can be found at www.aftpharm.com.
